Pancreatic Cancer Research

ResearcherSamsung Medical CenterActive in the last 2 years

Hye-Lim Jang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5100886437. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. Co-author DOI 10.1038/s41598-025-07668-1↗
  2. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Co-author DOI 10.1158/1535-7163.mct-11-0269↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seung Tae Kim · 2 shared papers, 2011–2025 · strength 0.29
  2. Kee‐Taek Jang · 2 shared papers, 2011–2025 · strength 0.29
  3. Young Suk Park · 2 shared papers, 2011–2025 · strength 0.29
  4. Joon Oh Park · 2 shared papers, 2011–2025 · strength 0.29
  5. Jung Yong Hong · 1 shared paper, 2025 · strength 0.27
  6. Ho Yeong Lim · 1 shared paper, 2011 · strength 0.02
  7. Jun Ho Yi · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.